Collaboration Agreement Patient Organisation

between

Bayer A/S
Company registration number (CVR) 16 08 98 18
Arne Jacobsens Allé 13, 6.
2300 København S
Denmark
(**"Bayer"**)

and

Danmarks Bløderforening
c/o Karen Binger Holm
Kompagnistræde 22, 2. sal baghuset
1208 København K
CVR-nr: 11802990
(**"Organisation"**)

Bayer and Organisation jointly referred to as "Parties".

Hereby the Parties agree as follows:

1. Project description

Organisation is active in the field of Hemophilia. Bayer is active in the field of Hemophilia. The Parties have agreed to collaborate on sponsoring one participant to an event named:

"EHC conference 2019" (European Haemophilia Consortium), October 4-6, Skopje, Northern Macedonia.

The purpose of the collaboration: There is strong solidarity and tradition in the international bleeding community for sharing knowledge and experience about life with bleeding disease. International research is crucial for the development and optimization of bleeding treatment, also in Denmark. International meetings and conferences are important arenas for gaining new knowledge and building relationships, and therefore the Danish Society of Diseases prioritizes participation. It is important for Bayer to gain insight into how "Danmarks Bløderforening" and patients are looking at above from a patient perspective.

The project is set out to be conducted in accordance with relevant laws and regulations including, but not limited to, the Ethical rules for Collaboration with Patient Groups etc. (Patientforeningskodeks) effective from 1/1- 2017, until further notice.

Activity:	EHC conference, European Haemophilia Consortium
Subject:	Hemophilia/Bleeding disorders
Date:	October 4-6 2019
Place:	Skopje
Venue:	Northern Macedonia.

2. Parties obligations

2.1. Bayer shall cover registration fee, travel, hotel accommodation and local transport for one participant from the Organisation.

2.2. The Organisation shall arrange, book travel and hotel accommodation and cover costs for participants' travel insurance. After the end of the meeting provide Bayer with a written report with their experience from the meeting . For example, important data / treatment guidelines for Hemophilia. (Report completed and reported to Bayer latest December 31, 2019).

3. Finance

3.1. Bayer has committed to finance the Project with the amount of max DK 6.860 (Six thousand eight hundred and sixty Danish Kroner). Bayer's finance is to support registration fee, travel, hotel accommodation and local transport for one participant from the Organisation. The costs necessary for conduct of the scientific and professional parts of the Project. The finance shall not be used for other costs such as; social activities, costs for ordinary business, internal activities or otherwise in conflict with applicable laws and regulations.

3.2. Any payments made by Bayer will be upon receipt of a proper invoice (to be issued in the name and on the letterhead of the Organisation) including reference- Purchase Order number and which meets all requirements according to applicable VAT requirements. Bayer shall pay within 45 days from receipt of the correct invoice.

3.3. Payment will be administrated and invoiced by the Organisation to Bayer on the following address.

Invoice address:
Bayer A/S
c/o Invoice reception point
D-51368 Leverkusen
Germany

Reference: PO number, will be communicated from Bayer via e-mail.

4. Transparency

4.1. The Parties agree that the content of this agreement can at any time be disclosed to a third party on request.

4.2. The parties agree that Bayer will upload the content of this Agreement on their website no later than project start and have it published until at least six months after the collaboration has ended.

4.3. The Parties declare that this Agreement is not in any way associated with any business or sales activities between the Parties hereto and in particular Organisation is by no means obligated to prescribe, recommend or purchase any goods from Bayer.

4.4. The parties agree that Bayer will at the end of each calendar year submit information regarding the collaboration to LIF in accordance with the applicable ethical rules.

4.5. The Parties warrant that the collaboration subject to this Agreement is in no way associated with influencing the Organisations opinions on professional and political issues.

4.6. The Parties declare that this Agreement is not in any way associated with any business or sales activities between the Parties hereto and in particular Organisation is by no means obligated to prescribe, recommend or purchase any goods from Bayer.

4.7. Bayer warrants that it does not hold any position within the organisation which might cause any unethical conflicts of interest for the purpose of this Agreement.

5. Contact

5.1. Bayer has appointed cecilia.berndt@bayer.com +46708825320 as contact person for enquires regarding this Agreement.

5.2. Organisation has appointed Karen Binger Holm, kbh@bloderforeningen.dk +45 33 14 55 05 as a contact person for enquiries relating to this Agreement

6. Usage of Logo- intellectual property trademark etc.

The parties should not use each other's logos without a prior written consent. When acquiring such consent, the requesting Party shall state for which specific purposes and in which way the logo and name shall be used.

7. Term

Duration of the project is October 4-6, 2019.

This contract comes into force upon signature of both Parties and continues until 191231.

8. Termination

If either Party is in breach or default in the performance of its obligations under this Agreement, and such breach or default continues for thirty (30) days after written notice by the other Party, may the non-breaching or non-defaulting Party have the right to terminate the Agreement with immediate effect.

9. Adverse Event/Product Technical Complaint

Under EU legislation Bayer and its contracted partners are obliged to fulfil certain Pharmacovigilance responsibilities stated in the Good Pharmacovigilance Practice (GVP) and relevant guidelines. Therefore Organisation agrees to provide to Bayer written reports of all Adverse Events, Product Technical Complaints regarding Bayer product(s) and service(s) covered by this Agreement that come to their attention by fax (+46 8 580 224 02) or e-mail (drugsafety.scand@bayer.com) within one (1) business day from receipt of information.

All known cases of exposure during pregnancy (including paternal exposure) and breastfeeding, misuse, abuse, lack of drug effect, overdose (accidental and intentional), medication error/use error, drug dependency, suspected transmission of an infectious agent, withdrawal syndrome, drug interactions, occupational exposure, off-label use, or unexpected Product benefit with respect to the Product(s) must be reported in the same manner as an Adverse Event /Product Technical Complaint.

For the purposes of this Agreement, an "Adverse Event "shall mean any untoward medical occurrence in a patient administered the Bayer product, which does not necessarily have to have a causal relationship with this treatment. A "Product Technical Complaint "is any report (written, electronic or verbal communication) about a potential or alleged failure of the Bayer product in its quality (including the identity, durability, reliability, safety, efficacy or performance) or suspected counterfeit. The complaint may or may not represent a potential risk to the patient.

10. Miscellaneous

10.1. This Agreement contains the entire agreement between the Parties. Any amendments to this Agreement shall be made in writing and duly signed by the Parties. If any provision of this Agreement is or becomes invalid or unenforceable, shall this not affect the remaining provisions hereof. The Parties shall in this case replace the invalid or unenforceable provision with a provision that is as close as possible to the economic effect of the invalid or unenforceable provision.

10.2. This Agreement shall be construed, controlled and interpreted by the Laws of Denmark. The Parties agree to the exclusive jurisdiction of the Copenhagen District Court as first instance.

This Agreement has been executed in two (2) copies, with each party receiving one (1) copy.

COPENHAGEN 2/10-2019

(Place) (Date)

ORGANISATION

Danmarks Bløderforening

Karen Binger Hellum

Signature

Danmarks Bløderforening
Kompagnistræde 22, 2.
1208 København K
Tlf. 33 14 55 05
CVR-nr. 11 80 29 90

CEO

Clarification of signature, title

Solna 2019-09-19

(Place) (Date)

BAYER A/S

Cecilia Berndt

Signature

Cecilia Berndt
Business Area Manager, Scandinavia

Solna 190919

(Place) (Date)

BAYER A/S

Catharina Linder

Signature

Catharina Linder
Sales & Marketing Assistant, Scandinavia

EHC CONFERENCE

4-6 October 2019
Skopje, North Macedonia

PRELIMINARY PROGRAMME

Friday 4 October	
08.00-19.00	Exhibition and Registration & Hospitality Desk
08.00-09.30	**General Assembly** (NMOs only)
09.30-10.00	*Tea/Coffee – Exhibition Area – iPad raffle*
10.00-12.00	**General Assembly (**NMOs only)
12.00-13.00	*Buffet Lunch*
13.00-13.45	**Opening** Chair: Brian O'Mahony
13.00-13.15	Haemophilia Care in Macedonia, a clinician overview *Dr Violeta Dejanova-Ilievska*
13.15-13.30	Life with haemophilia in Macedonia, a patient perspective *Bojan Chunde*
13.30-13.45	**30 Years of the EHC** *Brian O'Mahony*
13.45-15.00	**Overview of new treatments in haemophilia patients with and without inhibitors** Co-Chairs: Dan Hart & Thomas Sannié
13.45-14.15	EHL: experiences with Fc-fusion, albumin-fusion and PEG products in haemophilia A and B in Europe *Johannes Oldenburg*
14.15-14.45	How prophylaxis is changing in haemophilia *Beatrice Nolan*
14.45-15.00	Discussion
15.00-16.15	**Industry symposium 1 - Novo Nordisk on Women and Bleeding Disorders**
16.15-16.45	*Tea/Coffee – Exhibition Area*
16.45-18.00	**Industry symposium 2 - Sobi**
18.00-18.45	**Reception and Tapas**
18.45-19.00	**Conference Opening and Welcome** *Brief welcome by Cvetanka Nakeska, President, Hemolog* *Minister of Health (TBC)* *Brief welcome by Brian O'Mahony, President, EHC*
19.00-20.00	**Youth Debate**
20.00-22.30	**Buffet Supper**
	HCV Film; Women's Film; Lithuanian Film

Saturday 5 October	
08.00-19.00	Exhibition and Registration & Hospitality Desk
08.30-09.45	**Industry Symposium 3 - Sanofi**
09.45 -10.15	*Tea/Coffee – Exhibition Area*
10.15-11.45	**Quality of life & patient experience on first available non-replacement therapy** Co-Chairs: Flora Peyvandi & Miguel Crato

Danmarks Bløderforening
Kompagnistræde 22, 2. sal baghuset
1208 København K
Tlf. 3314 5505
www.bloderforeningen.dk

Bayer

Den 13. september 2019

Ansøgning om støtte til deltagelse i EHC konference 2019

Danmarks Bløderforening vil med denne ansøgning søge Bayer om støtte til at sende en repræsentant til EHC konference d. 4-6. oktober 2019 i Skopje, Nordmakedonien.

Der er i det internationale blødersamfund en stærk solidaritet og tradition for at dele viden og erfaring om livet med blødersygdom. Ligeledes er international forskning afgørende for udvikling og optimering af bløderbehandlingen, også i Danmark. Internationale møder og konferencer er vigtige arenaer for at opnå ny viden og udbygge relationer og derfor prioriterer Danmarks Bløderforening deltagelse højt.

I år sender Danmarks Bløderforening fire repræsentanter til EHC konferencen i Skopje. Delegationen skal blandt andet skabe opmærksomhed om det danske værtsskab for EHC konferencen i København i 2020.

Vedlagt er program for EHC konferencen. Med denne ansøgning søges om støtte til at dække deltagergebyr, rejse, ophold og lokal transport for en deltager:

Budget DKR		
Deltagergebyr	200 Euro	1.493 kr.
Ibis Hotel City Centre	3 nætter	1.567 kr.
Fly	Tur/retur	3.000 kr.
Transport lokalt	Estimat	800 kr.
I alt		**6.860 kr.**

Foreningen dækker omkostning til deltagernes rejseforsikring.

Enhver støtte er velkommen og modtages med tak. Kontakt mig gerne, hvis der er spørgsmål til ansøgningen.

Venlig hilsen

Karen Binger Holm
Sekretariatsleder, Danmarks Bløderforening